What is the target price for Regeneron Pharmaceuticals (regn) stock?
18 brokers have issued 1 year target prices for Regeneron Pharmaceuticals' shares. Their predictions range from $320.00 to $480.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $385.38 in the next year.
What is Regeneron Pharmaceuticals P/B ratio?
Regeneron Pharmaceuticals has a P/B Ratio of 6.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Is Regeneron Pharmaceuticals a buy right now?
Does REGON Pharmaceuticals stock pay a dividend?
Regeneron Pharmaceuticals does not currently pay a dividend. Regeneron Pharmaceuticals does not have a long track record of dividend growth. In the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought.
Does regn stock pay a dividend?
A company's dividend expressed as a percentage of its current stock price. REGN is not currently paying a regular dividend. The total number of shares of a security that have been sold short and not yet repurchased. Percentage change in short interest from the previous report to the most recent report.
See more
Is Regeneron stock a buy now?
There are currently 2 sell ratings, 5 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Regeneron Pharmaceuticals stock.
Will Regeneron stock go back up?
The 22 analysts offering 12-month price forecasts for Regeneron Pharmaceuticals Inc have a median target of 684.00, with a high estimate of 790.00 and a low estimate of 536.00. The median estimate represents a +16.72% increase from the last price of 586.02.
Does Regeneron stock pay dividends?
Does Regeneron pay a cash dividend? No, we have never paid a cash dividend nor do we expect to pay any dividends in the foreseeable future.
Why is Regeneron going down?
In 2022's first quarter, Regeneron's sales were down 40% compared to 2021's fourth quarter. The gaping hole in the company's financials was due to REGEN-COV, its COVID-19 treatment, which didn't generate any revenue in the U.S. in Q1.
Is REGN a good buy now?
The financial health and growth prospects of REGN, demonstrate its potential to outperform the market. It currently has a Growth Score of A. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of F.
Is Regeneron a stable company?
Regeneron is a good company to work for. They take care of their employees and do community outreach. Comp and benefits are fair as well. Overall it is a solid company.
Who has Regeneron stock?
Top 10 Owners of Regeneron Pharmaceuticals IncStockholderStakeShares ownedJPMorgan Investment Management, I...3.42%3,697,695Wellington Management Co. LLP2.68%2,890,203Loomis, Sayles & Co. LP2.36%2,548,047Dodge & Cox2.07%2,237,0636 more rows
Does Vertex pay a dividend?
Vertex Pharmaceuticals (NASDAQ: VRTX) does not pay a dividend.
Why is Regeneron so cheap?
Investors are paying a discount on Regeneron's earnings because its COVID-19 revenue will drop off.
Is Regeneron a publicly traded company?
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2022 financial and operating results on Wednesday, August 3, 2022, before the U.S. financial markets open.
Should I buy or sell Regeneron Pharmaceuticals stock right now?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently...
What is Regeneron Pharmaceuticals' stock price forecast for 2022?
19 analysts have issued 1 year price targets for Regeneron Pharmaceuticals' shares. Their forecasts range from $536.00 to $844.00. On average, they...
How has Regeneron Pharmaceuticals' stock price performed in 2022?
Regeneron Pharmaceuticals' stock was trading at $631.52 on January 1st, 2022. Since then, REGN shares have decreased by 9.5% and is now trading at...
When is Regeneron Pharmaceuticals' next earnings date?
Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecas...
How were Regeneron Pharmaceuticals' earnings last quarter?
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its earnings results on Wednesday, May, 4th. The biopharmaceutical company reported $11.49...
Who are Regeneron Pharmaceuticals' key executives?
Regeneron Pharmaceuticals' management team includes the following people: Dr. Leonard S. Schleifer M.D. , Ph.D., Founder, Pres, CEO & Director (...
What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?
423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com . Leonard S. Schleifer has an approval rating of 87%...
Who are some of Regeneron Pharmaceuticals' key competitors?
Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Bi...
What other stocks do shareholders of Regeneron Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NV...
When did Regeneron buy back its stock?
When will Regeneron release its earnings?
Regeneron Pharmaceuticals declared that its board has initiated a stock buyback program on Tuesday, November 5th 2019 , which allows the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 2.9% of its shares through open market purchases.
When is Regeneron earnings call?
Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021. View our earnings forecast for Regeneron Pharmaceuticals.
How much does Regeneron make?
Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, August 5th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.